Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

MYLAN INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Mylan Inc. : Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2013 | 08:50am CEST

StockCall.com Provides Stock Research on Mylan Inc., Teva Pharmaceutical Industries Ltd, Covidien plc, Valeant Pharmaceuticals International Inc., and Zoetis Inc.

New York City, New York -- (May 09, 2013)

Equity markets edged higher on Wednesday after struggling initially. It was yet another historic day as the Dow Jones and the S&P 500 closed at fresh all-time high levels. Market sentiment was lifted by better-than-expected trade data from China. Improving global economic outlook coupled with ultra-loose monetary policies from developed world central banks have boosted investors? risk appetite. Yesterday, the healthcare sector was among the best performers in the S&P 500. Among the major movers in this sector were Mylan Inc. (NASDAQ: MYL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc (NYSE: COV), Vertex Pharmaceuticals International Inc. (NYSE: VRX), and Zoetis Inc. (NYSE: ZTS). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, TEVA, COV, VRX, and ZTS at

www.stockcall.com/registration

Mylan Inc.?s shares edged lower in trading on Wednesday. The stock traded between $29.30 and $29.93 before finishing the day 1.21% lower at $29.33 on volume of 4.41 million. Despite the losses yesterday, Mylan?s shares have gained nearly 1.50% in the last three trading sessions. Year-to-date, the stock has gained more than 6.80%, underperforming the broad market. Shares of MYL are currently trading more than 6% below their 52-week high. Sign up today to read the free research report on MYL at

www.StockCall.com/MYL050913.pdf

Shares of Teva Pharmaceutical Industries Ltd. edged higher in yesterday?s trading session; however, the gains were limited. The stock closed 0.18% higher at $38.42 on volume of 2.94 million. Teva Pharmaceutical?s shares are currently trading close to their 52-week low of $38.33. The stock is also trading below its 50-day and 200-day moving averages which is a bearish signal. However, the stock?s MACD has just crossed above the signal line which suggests that market sentiment has turned bearish. Register to download the free technical analysis on TEVA at

www.StockCall.com/TEVA050913.pdf

Shares of Covidien Plc edged higher on Wednesday, tracking gains in the broad market. The stock touched an intraday high of $65.88 before finishing the day 0.98% higher at $65.88 on volume of 2.89 million. Covidien?s shares have gained nearly 2.40% in the last three trading sessions. The stock has seen a series of highs over the past week which is a bullish signal. The positive trend is further confirmed by recent volume activity, and the stock?s MACD chart. Free report on COV can be accessed by registering at

www.StockCall.com/COV050913.pdf

Valeant Pharmaceuticals International Inc.?s shares struggled in yesterday?s trading session. The stock ended the day 0.28% lower at $73.86 on volume of 713,719. The company?s shares are currently trading close to their 52-week high of $76.57. The stock has gained nearly 23.60% so far in 2013 as compared to a gain of nearly 14.50% for the S&P 500. The stock is currently trading above its 50-day and 200-day moving averages.Register withStockCall and download the research on VRX for free at

www.StockCall.com/VRX050913.pdf

Shares of Zoetis Inc. rose in trading on Wednesday. The stock touched an intra-day high of $33.44 before finishing the day 1.16% higher at $33.26 on volume of 1.03 million. Zoetis?shares have underperformed the S&P 500 so far in 2013, gaining nearly 7.50%. The stock?s MACD is currently trading above the signal line and the zero-line which is a bullish signal. Shares of ZTS are trading nearly 6% below their 52-week high. Read the full free research on ZTS by signing up to StockCall at

www.StockCall.com/ZTS050913.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: [email protected]

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
06/18MYLAN : Launches Generic Angiomax® Injection
PR
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
06/14FDA Rejects Mylan's Asthma Generic Over Deficiencies -- Market Mover
DJ
06/13MYLAN : Provides Statement on Generic Advair Diskus®
PU
06/11MYLAN : Americares Honors Mylan with Power of Partnership Award
PU
06/04MYLAN : U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb..
PU
06/01MYLAN : and Biocon to Present New Data at the American Society of Clinical Oncol..
PU
More news
News from SeekingAlpha
2015Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript 
2015Mylan Q4 revenues up 15%, Specialty up 38% 
2015Mylan (MYL) Q4 2014 Results - Earnings Call Webcast 
2015Mylan EPS in-line, beats on revenue 
2015Notable earnings after Monday?s close 
Financials ($)
Sales 2018 12 272 M
EBIT 2018 3 781 M
Net income 2018 1 295 M
Debt 2018 13 342 M
Yield 2018 -
P/E ratio 2018 14,89
P/E ratio 2019 12,28
EV / Sales 2018 2,72x
EV / Sales 2019 2,39x
Capitalization 20 035 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 49,1 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC20 035
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189